🇺🇸 FDA
Pipeline program

Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

111-302

Phase 3 small_molecule active

Quick answer

Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection for Achondroplasia is a Phase 3 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
BioMarin International Limited
Indication
Achondroplasia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials